BIA regional focus: Glasgow at the cutting edge of digital advances
The BIA is delighted to run another Scottish regional event, this year to be held virtually.
Companies in Glasgow are at the forefront of the new digital approach to drug discovery, development and manufacturing, and this event will celebrate their work by shining a spotlight on three organisations in particular:
- "Riding the wave of digital chemistry to improve outcome and reproducibility" - Mark Warne, DeepMatter
- "Developments in digital technologies and microfactories" - Andrea Johnston, CMAC
- "Advanced digital solutions in the pharmaceutical industry" - Dave Tudor, Medicines Manufacturing Innovation Centre
After these presentations, the speakers will join a panel discussion to discuss the role of digital developments in the sector, and to answer any questions from the audience.
The afternoon will end with a chance to network remotely using Remo, a platform designed to mimic in-person networking as closely as possible.
15.00 Sign in and networking
15.15 BIA update
15:25 Presentations followed by panel discussion and Q&A
17:30 Event closes
We are excited to bring you this BIA regional focused networking event in virtual format.
You will be able to join us online to network and, similar to an in-person event, move from virtual table to table to mingle with other attendees. The platform we will be using also includes useful features which will allow you to message directly with other attendees and share LinkedIn details to connect. There is also a general chat for all attendees.
During the presentations/discussion you will be able to submit and vote on audience questions and we will try our best to cover everything in the time allocated.
What are the technical requirements to attend the virtual event?
- There is no software installation or download required.
- Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone).
- You will need to use one of the supported browsers to have the best user experience:
Chrome, Safari, or Firefox.
- Please do a system check in advance of the event, to ensure you will be able to join without issue.
If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.
BIA members: Free
Non-members: £30 +VAT
By registering for this event you accept our Terms & Conditions.
In case of any issues registering for the event, please contact us at firstname.lastname@example.org
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Andrea is Programme Manager of CMAC, ESPRC Future Manufacturing Research Hub in Continuous Manufacturing and Advanced Crystallisation.
CMAC was cocreated with industry in 2011 and it’s vision is to transform medicines development and manufacture, through delivering predictive design tools and novel integrated modular MicroFactories. Led from University of Strathclyde it has six partner Universities (Bath, Cambridge, Leeds, Loughborough, Sheffield, and Imperial College London) and eight global pharma Tier 1 members (AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Roche and Takeda) in addition to a number of Tier 2 members, innovation spokes and strategic partners. An ambitious research programme and exemplar technical translation activities led from world-class facilities provide a nurturing environment for training the workforce of the future.
Andrea also works across the digital manufacturing community and is on Executive Group for Connected Everything II Network, part of MMIP Skills and a keen advocate for E,D &I in STEM.
Prior to joining CMAC in 2011, Andrea was a research fellow in solid-state chemistry with a keen interest in pioneering machine learning for crystallisation outcomes.
Specialising in life sciences and healthcare, Alix Mackay provides marketing training and capabilities to high-growth businesses, start-ups and entrepreneurial academics. She also serves as the Chief Commercial Officer for Nuchido, specialists in the field of antiaging science. Alix’s background is in the pharmaceutical industry where she held a number of commercial leadership roles at companies such as Servier and Amgen where she launched a therapeutic monoclonal antibody for the treatment of osteoporosis, a joint venture with GSK. Based in Glasgow, Alix is a member of Scotland’s Life Sciences Industry Leadership Group, a member of the Royal Society of Chemistry and host of The Scotsman’s annual Life Sciences Conference.
Dave joined CPI in January 2019 as Managing Director for the Medicines Manufacturing Innovation Centre (MMIC).
The MMIC is a collaboration between industry, academia and government. CPI is working together with the University of Strathclyde, AstraZeneca and GSK. With government support from Scottish Enterprise and Innovate UK, the MMIC will be located in Renfrewshire, Scotland.
The MMIC is a unique facility to enable new and disruptive pharmaceutical manufacturing technologies to be proven at scale in a GMP-capable environment. This will speed next-generation process adoption with reduced risk, cost and time, and provide a unique environment for the training of personnel in the techniques of future manufacturing processes.
Prior to this Dave worked for GSK, joining in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience with the company carrying out a number of Technical, Compliance and Manufacturing leadership roles, before becoming VP Head of GMS Strategy in 2017, with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.
Dave is married with 4 children and lives in Ayrshire. He enjoys all sports, particularly football, is a keen reader of Scottish history and cooks to relax.
Mark Warne was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of Open Orphan plc and Ixico plc.
Thank you to our event partner
Thank you to our event supporters